Skip to content

Swiss Atrial Fibrillation Cohort Study

Swiss Atrial Fibrillation Cohort Study - SWISS AF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02105844
Acronym
SWISS-AF
Enrollment
2415
Registered
2014-04-07
Start date
2014-03-31
Completion date
2030-03-31
Last updated
2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, dementia, cognitive dysfunction, stroke, Magnetic resonance imaging

Brief summary

Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged \>65 years will be included and followed on a yearly basis. Yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up. The main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.

Interventions

None listed

Sponsors

Swiss National Science Foundation
CollaboratorOTHER
Medical Image Analysis Center (MIAC) Basel
CollaboratorUNKNOWN
Schiller AG Baar
CollaboratorUNKNOWN
Clinical Trial Unit, University Hospital Basel, Switzerland
CollaboratorOTHER
Cardiovascular Research Institute (CRIB) Basel
CollaboratorUNKNOWN
Cardiocentro Ticino
CollaboratorOTHER
University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* atrial fibrillation documented within the last 24 months * age \>=45 years

Exclusion criteria

* acute illness * inability to provide informed consent * Only short episodes of reversible forms of atrial fibrillation

Design outcomes

Primary

MeasureTime frame
Stroke or systemic embolism2018 (after an average of 2.5 years of follow-up)

Secondary

MeasureTime frame
Hospitalization for heart failure2018 (after an average of 2.5 years of follow-up)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026